← Eichor
Study identifier: NCT07563153 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Impact of Optimized Pacing Strategies on Clinical and Hemodynamic Outcomes in Heart Failure Patients With Pacemaker

Condition: Heart Failure · Bradycardia  ·  Sponsor: Samsung Medical Center

PhaseNA
Planned participants106
Who can joinAll sexes, 19 Years to no upper limit
Healthy volunteersNo

About this study

This study aims to evaluate the clinical impact of an optimized pacing strategy in patients with heart failure. * Intervention: Adjustment of the pacemaker lower rate limit to an individualized, hemodynamically optimized heart rate. * Primary Endpoint: Heart failure symptoms, assessed by the Kansas City Cardiomyopathy Questionnaire score. * Hypothesis: In patients with heart failure requiring permanent pacing, an optimized pacing strategy will lead to a significant improvement in heart failure symptoms (Kansas City Cardiomyopathy Questionnaire score) at 12 months compared with the conventional pacing strategy.

This description comes directly from the study's public registry record.

Talk to the study team

Juwon Kim, MD  ·  82-10-2079-8154  ·  abcd186a@naver.com

Always discuss trial participation with your own doctor first.

Locations (1)

Samsung Medical CenterSeoul, Seoul, South KoreaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07563153